Restless legs syndrome, susceptibility to, 6

Summary

Restless legs syndrome, susceptibility to, 6 (MONDO:0012636) is a disease and 1 clinical trial. A subtype of restless legs syndrome, susceptibility to — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	restless legs syndrome, susceptibility to, 6
Mondo ID	MONDO:0012636
OMIM	611185
UMLS	C1970020
MedGen	370810
Is cancer (heuristic)	no

Also known as: periodic limb movements in sleep · restless legs syndrome 6 · restless legs syndrome, susceptibility to, 6 · RLS6

Disease family

Classification path: disease susceptibility › inherited disease susceptibility › restless legs syndrome, susceptibility to › restless legs syndrome, susceptibility to, 6

Related subtypes (7): restless legs syndrome, susceptibility to, 1, restless legs syndrome, susceptibility to, 2, restless legs syndrome, susceptibility to, 3, restless legs syndrome, susceptibility to, 4, restless legs syndrome, susceptibility to, 5, restless legs syndrome, susceptibility to, 7, restless legs syndrome, susceptibility to, 8

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01365364	Not specified	COMPLETED	Dopamine Transporter Density Profiles in Patients With Periodic Limb Movements